WIN-Partners CoTSE:3183 +0.31%63 ROA % is 4.55% as of Mar. 2026, which is 2% below its 10-year median of 4.63. GuruFocus rates TSE:3183 with a GF Score™ of 63/100 and a GF Value™ of 円1,522.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, WIN-Partners Co ranks better than 74.58% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. WIN-Partners Co's annualizedNet Income for the quarter that ended in Mar. 2026 was 円2,211 Mil.
WIN-Partners Co's average Total Assets over the quarter that ended in Mar. 2026 was 円48,579 Mil. Therefore, WIN-Partners Co's annualized ROA % for the quarter that ended in Mar. 2026 was 4.55%.
The historical rank and industry rank for WIN-Partners Co's ROA % or its related term are showing as below:
TSE:3183'
s ROA % Range Over the Past 10 Years
Min: 3.91 Med: 4.63 Max: 8.66
Current: 4.42
During the past 13 years, WIN-Partners Co's highest ROA % was 8.66%. The lowest was 3.91%. And the median was 4.63%.
TSE:3183's ROA % is ranked better than 74.58% of 118
companies
in the Medical Distribution industry
Industry Median: 2.215
vs TSE:3183: 4.42
WIN-Partners Co (TSE:3183) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
WIN-Partners Co ROA % Related Terms
WIN-Partners Co ROA % Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, WIN-Partners Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's ROA % distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
WIN-Partners Co (TSE:3183) has a ROA % of 4.55% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on WIN-Partners Co and its competitors. This is near median its historical median of 4.63. Over the past decade, WIN-Partners Co's ROA % has ranged from 3.91 to 8.66. According to the industry distribution chart, WIN-Partners Co ranks #30 out of 118 companies in the Medical Distribution industry, placing it in the top 25.4%.
Is WIN-Partners Co's ROA % too high?
WIN-Partners Co's current ROA % of 4.55% is near median its 10-year median of 4.63. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 8.66. The Medical Distribution industry median ROA % is 2.22. WIN-Partners Co's value of 4.55% is 105.4% above this industry median. Based on the distribution chart, WIN-Partners Co ranks #30 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, WIN-Partners Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's ROA % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #30 out of 118 companies for ROA %. This puts WIN-Partners Co in the upper half of its industry. The industry median ROA % is 2.22. WIN-Partners Co's value of 4.55% is 105.4% above this benchmark. Historically, WIN-Partners Co's own ROA % has ranged from 3.91 to 8.66 over the past decade. While the company's 10-year median is 4.63 vs. the industry median of 2.22, WIN-Partners Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.22, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current ROA % of 4.55% is 105.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median ROA % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current ROA % is 4.55%, which is near median its own 10-year median of 4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,522.55, compared to a current price of 円1,285.00 — trading 15.6% below its estimated fair value. The current ROA % is 4.55%, which is near median its 10-year median of 4.63 and 105.4% above the Medical Distribution industry median of 2.22. WIN-Partners Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current ROA % is 4.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,285.00 is trading 15.6% below its estimated GF Value™ of 円1,522.55.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
ROA %: 4.55% (near median its 10-year median of 4.63)
GF Value™: 円1,522.55 vs. price of 円1,285.00 (15.6% below fair value)
Industry Position: 105.4% above the Medical Distribution median (#30 of 118)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
63GF Score
Get the complete analysis for TSE:3183
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
